Goldman Predicts U.S. May Have a Covid-19 Vaccine by End of Year

July 17, 2020, 12:17 PM

The first vaccine for Covid-19 could be available in the U.S. later this year, Goldman Sachs analysts forecast.

The potential for Moderna Inc. to file interim results with U.S. regulators from a 30,000-patient trial due to start by July 27 is underappreciated, analysts led by Salveen Richter said. The chances of success in 2020 are enhanced further by four other vaccine programs slated to enter into the final research phase of testing sometime this summer, according to Goldman.

Those experimental inoculations expected to start large-scale testing this summer are from Pfizer Inc. in partnership with BioNtech SE; AstraZeneca Plc with ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.